Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Lab Invest. 2015 Aug 17;95(11):1278–1290. doi: 10.1038/labinvest.2015.104

Figure 5.

Figure 5

Effect of pharmacologic EZH2 inhibition on EZH2 and H3K27me3 levels in human RB cells. (A–D) Western blot of whole cell lysates of Y79 (A,B) and WERI-Rb1 (W-Rb1, C,D) following 48 h of treatment with indicated EZH2 inhibitors, GSK126 (A, C) and SAH-EZH2 (B, D). (E–F) Western blot of histone methylation status in whole cell lysates of WERI-Rb1 and Y79 following incubation with (E) indicated concentrations of GSK126 for 48 h or indicated periods of treatment at 5 µM of GSK126 or (F) indicated concentrations of SAH-EZH2 for 48 h. H3K27Me3 represents the histone methylation target of EZH2, whereas H3K4Me3 represents a site unaffected by the enzyme (negative control). H3 represents total histone 3 protein levels, which should also be unaffected by EZH2 modulation.